WM
Second-line therapy comprising standard rituximab plus bendamustine and bortezomib was effective and well-tolerated as ...
A phase II study presented at the 2021 Annual Meeting & Exposition of the American Society of Hematology, reported ...
The analysis was a retrospective cohort analysis of 32 consecutive WM patients treated with ASCT.
Tirabrutinib was designed to improve the safety and efficacy of ibrutinib with a more favorable toxicity profile.
Researchers discerned baseline demographics, symptoms, and survival outcomes of WM among different ethnic groups.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC. All rights reserved.